JCI The Journal of Clinical Investigation

iPSC-derived β cells model diabetes due to glucokinase deficiency

Haiqing Hua, … , Rudolph L. Leibel, Dieter Egli

J Clin Invest. 2017;127(3):1115-1115. https://doi.org/10.1172/JCI92775.

Retraction

Original citation: J Clin Invest. 2013;123(7):3146–3153. https://doi.org/10.1172/JCI67638 Citation for this retraction: J Clin Invest. 2017;127(3):1115. https://doi.org/10.1172/JCI92775 The corresponding authors were made aware of karyotype abnormalities through a routine quality control test of pluripotent stem cells used in the studies reported in this paper. After extensive internal review and genetic analysis, they found that the karyotypes of some of the cells used for the experiments reported were abnormal and that the normal karyotypes shown in Figure 1 and Supplemental Figure 2 were not from cell lines used in the study. They also cannot confirm the endonuclease-mediated correction of the mutant GCK G299R allele. H. Hua takes responsibility for the characterization and presentation of cell line karyotypes and the genetic manipulations. Because of these discrepancies, the authors wish to retract the article. They apologize for these errors and for any inconvenience caused to others.

Retraction

iPSC-derived β cells model diabetes due to glucokinase deficiency

Haiqing Hua, Linshan Shang, Hector Martinez, Matthew Freeby, Mary Pat Gallagher, Thomas Ludwig, Liyong Deng, Ellen Greenberg, Charles LeDuc, Wendy K. Chung, Robin Goland, Rudolph L. Leibel, and Dieter Egli

Original citation: *J Clin Invest*. 2013;123(7):3146–3153. https://doi.org/10.1172/JCI67638.

Citation for this retraction: *J Clin Invest*. 2017;127(3):1115. https://doi.org/10.1172/JCI92775.

The corresponding authors were made aware of karyotype abnormalities through a routine quality control test of pluripotent stem cells used in the studies reported in this paper. After extensive internal review and genetic analysis, they found that the karyotypes of some of the cells used for the experiments reported were abnormal and that the normal karyotypes shown in Figure 1 and Supplemental Figure 2 were not from cell lines used in the study. They also cannot confirm the endonuclease-mediated correction of the mutant GCK G299R allele. H. Hua takes responsibility for the characterization and presentation of cell line karyotypes and the genetic manipulations. Because of these discrepancies, the authors wish to retract the article. They apologize for these errors and for any inconvenience caused to others.

Retraction

Blocking mitochondrial calcium release in Schwann cells prevents demyelinating neuropathies

Sergio Gonzalez, Jade Berthelot, Jennifer Jiner, Claire Perrin-Tricaud, Ruani Fernando, Roman Chrast, Guy Lenaers, and Nicolas Tricaud

Original citation: *J Clin Invest*. 2016;126(3):1023–1038. https://doi.org/10.1172/JCI84505.

Citation for this retraction: *J Clin Invest*. 2017;127(3):1115. https://doi.org/10.1172/JCI92100.

Following an institutional investigative review of multiple errors in data presentation in this paper, including several instances of reuse of the same images to represent independent samples in Supplemental Figures 7 and 11, the Editorial Board is retracting this paper. The institutional review found no evidence of intention to falsify results and concluded that errors were made due to negligence during the assembly of figures. The institutional review panel did not question in any way the authenticity of the published results. The paper is being retracted because *JCI* editorial policy prohibits image duplication and misrepresentation of data.